Transcriptome Profiling of Pediatric Core Binding Factor AML

被引:15
作者
Hsu, Chih-Hao [1 ]
Cu Nguyen [1 ]
Yan, Chunhua [1 ]
Ries, Rhonda E. [2 ]
Chen, Qing-Rong [1 ]
Hu, Ying [1 ]
Ostronoff, Fabiana [2 ]
Stirewalt, Derek L. [2 ]
Komatsoulis, George [1 ]
Levy, Shawn [3 ]
Meerzaman, Daoud [1 ]
Meshinchi, Soheil [2 ]
机构
[1] NCI, Ctr Biomed Informat & Informat Technol, Rockville, MD 20850 USA
[2] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[3] Hudson Alpha Inst Biotechnol, Huntsville, AL USA
来源
PLOS ONE | 2015年 / 10卷 / 09期
关键词
ACUTE MYELOID-LEUKEMIA; FUSION GENES; RNA-SEQ; DIFFERENTIAL EXPRESSION; SEQUENCING DATA; CBF-BETA; HOX; IDENTIFICATION; DISCOVERY; CANCER;
D O I
10.1371/journal.pone.0138782
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The t(8; 21) and Inv(16) translocations disrupt the normal function of core binding factors alpha (CBFA) and beta (CBFB), respectively. These translocations represent two of the most common genomic abnormalities in acute myeloid leukemia (AML) patients, occurring in approximately 25% pediatric and 15% of adult with this malignancy. Both translocations are associated with favorable clinical outcomes after intensive chemotherapy, and given the perceived mechanistic similarities, patients with these translocations are frequently referred to as having CBF-AML. It remains uncertain as to whether, collectively, these translocations are mechanistically the same or impact different pathways in subtle ways that have both biological and clinical significance. Therefore, we used transcriptome sequencing (RNA-seq) to investigate the similarities and differences in genes and pathways between these subtypes of pediatric AMLs. Diagnostic RNA from patients with t(8; 21) (N = 17), Inv(16) (N = 14), and normal karyotype (NK, N = 33) were subjected to RNA-seq. Analyses compared the transcriptomes across these three cytogenetic subtypes, using the NK cohort as the control. A total of 1291 genes in t(8;21) and 474 genes in Inv(16) were differentially expressed relative to the NK controls, with 198 genes differentially expressed in both subtypes. The majority of these genes (175/198; binomial test p-value < 10(-30)) are consistent in expression changes among the two subtypes suggesting the expression profiles are more similar between the CBF cohorts than in the NK cohort. Our analysis also revealed alternative splicing events (ASEs) differentially expressed across subtypes, with 337 t(8;21)-specific and 407 Inv(16)-specific ASEs detected, the majority of which were acetylated proteins (p = 1.5x10(-51) and p = 1.8x10(-54) for the two subsets). In addition to known fusions, we identified and verified 16 de novo fusions in 43 patients, including three fusions involving NUP98 in six patients. Clustering of differentially expressed genes indicated that the homeobox (HOX) gene family, including two transcription factors (MEIS1 and NKX2-3) were down-regulated in CBF compared to NK samples. This finding supports existing data that the dysregulation of HOX genes play a central role in biology CBF-AML hematopoiesis. These data provide comprehensive transcriptome profiling of CBF-AML and delineate genes and pathways that are differentially expressed, providing insights into the shared biology as well as differences in the two CBF subsets.
引用
收藏
页数:18
相关论文
共 56 条
[11]   Histone Deacetylase Activity Modulates Alternative Splicing [J].
Hnilicova, Jarmila ;
Hozeifi, Samira ;
Duskova, Eva ;
Icha, Jaroslav ;
Tomankova, Tereza ;
Stanek, David .
PLOS ONE, 2011, 6 (02)
[12]   Low frequency of DNMT3A mutations in pediatric AML, and the identification of the OCI-AML3 cell line as an in vitro model [J].
Hollink, I. H. I. M. ;
Feng, Q. ;
Danen-van Oorschot, A. A. ;
Arentsen-Peters, S. T. C. J. M. ;
Verboon, L. J. ;
Zhang, P. ;
de Haas, V. ;
Reinhardt, D. ;
Creutzig, U. ;
Trka, J. ;
Pieters, R. ;
van den Heuvel-Eibrink, M. M. ;
Wang, J. ;
Zwaan, C. M. .
LEUKEMIA, 2012, 26 (02) :371-373
[13]   NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern [J].
Hollink, Iris H. I. M. ;
van den Heuvel-Eibrink, Marry M. ;
Arentsen-Peters, Susan T. C. J. M. ;
Pratcorona, Marta ;
Abbas, Saman ;
Kuipers, Jenny E. ;
van Galen, Janneke F. ;
Beverloo, H. Berna ;
Sonneveld, Edwin ;
Kaspers, Gert-Jan J. L. ;
Trka, Jan ;
Baruchel, Andre ;
Zimmermann, Martin ;
Creutzig, Ursula ;
Reinhardt, Dirk ;
Pieters, Rob ;
Valk, Peter J. M. ;
Zwaan, C. Michel .
BLOOD, 2011, 118 (13) :3645-3656
[14]   OmicCircos: A Simple-to-Use R Package for the Circular Visualization of Multidimensional Omics Data [J].
Hu, Ying ;
Yan, Chunhua ;
Hsu, Chih-Hao ;
Chen, Qing-Rong ;
Niu, Kelvin ;
Komatsoulis, George A. ;
Meerzaman, Daoud .
CANCER INFORMATICS, 2014, 13 :13-20
[15]   Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources [J].
Huang, Da Wei ;
Sherman, Brad T. ;
Lempicki, Richard A. .
NATURE PROTOCOLS, 2009, 4 (01) :44-57
[16]   A role for RUNX1 in hematopoiesis and myeloid leukemia [J].
Ichikawa, Motoshi ;
Yoshimi, Akihide ;
Nakagawa, Masahiro ;
Nishimoto, Nahoko ;
Watanabe-Okochi, Naoko ;
Kurokawa, Mineo .
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2013, 97 (06) :726-734
[17]   Structural alterations in the transcription factor PEBP2/CBF linked to four different types of leukemia [J].
Ito, Y .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1996, 122 (05) :266-274
[18]   TopHat-Fusion: an algorithm for discovery of novel fusion transcripts [J].
Kim, Daehwan ;
Salzberg, Steven L. .
GENOME BIOLOGY, 2011, 12 (08)
[19]   ChimerDB 2.0-a knowledgebase for fusion genes updated [J].
Kim, Pora ;
Yoon, Suhyeon ;
Kim, Namshin ;
Lee, Sanghyun ;
Ko, Minjeong ;
Lee, Haeseung ;
Kang, Hyunjung ;
Kim, Jaesang ;
Lee, Sanghyuk .
NUCLEIC ACIDS RESEARCH, 2010, 38 :D81-D85
[20]   The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials [J].
Kottaridis, PD ;
Gale, RE ;
Frew, ME ;
Harrison, G ;
Langabeer, SE ;
Belton, AA ;
Walker, H ;
Wheatley, K ;
Bowen, DT ;
Burnett, AK ;
Goldstone, AH ;
Linch, DC .
BLOOD, 2001, 98 (06) :1752-1759